Is There Something Wrong With the Scientific Method?

Sep 16, 2011

By Jonah Lehrer - The New Yorker

On September 18, 2007, a few dozen neuroscientists, psychiatrists, and drug-company executives gathered in a hotel conference room in Brussels to hear some startling news. It had to do with a class of drugs known as atypical or second-generation antipsychotics, which came on the market in the early nineties. The drugs, sold under brand names such as Abilify, Seroquel, and Zyprexa, had been tested on schizophrenics in several large clinical trials, all of which had demonstrated a dramatic decrease in the subjects' psychiatric symptoms. As a result, second-generation antipsychotics had become one of the fastest-growing and most profitable pharmaceutical classes. By 2001, Eli Lilly's Zyprexa was generating more revenue than Prozac. It remains the company's top-selling drug.

But the data presented at the Brussels meeting made it clear that something strange was happening: the therapeutic power of the drugs appeared to be steadily waning. A recent study showed an effect that was less than half of that documented in the first trials, in the early nineteen-nineties. Many researchers began to argue that the expensive pharmaceuticals weren't any better than first-generation antipsychotics, which have been in use since the fifties. "In fact, sometimes they now look even worse," John Davis, a professor of psychiatry at the University of Illinois at Chicago, told me.

View the newsletter | Print this Article | Facebook | Twitter

« Back to all news

 
Home Learn More Practitioners Courses Membership Testimonials
Who We Are BodyTalk Find a Practitioner Find a Course Join Today Videos
Get the Newsletter Access Become a Practitioner Founder's Courses Membership at a Glance Foundation
Contact Us Breakthrough Practitioner Levels Beginner's Courses Membership Levels Store
FAQ Mindscape BodyTalk as a Career View All Instructors Membership Prices Media Kit
Privacy Policy News Invest in Yourself Course Listing




Copyright © 2005 - 2018 International BodyTalk Association (IBA) | Legal